Ribeiro, S., Do Sameiro Faria, M., Mascarenhas-Melo, F., Freitas, I., et al. (2012). Main determinants of PON1 activity in hemodialysis patients. American Journal of Nephrology, 36(4), 317 - 323.

Costa, E., Rocha, S., Rocha-Pereira, P., Reis, F., et al. (2009). Effect of hemodialysis procedure in prohepcidin serum levels in regular hemodialysis patients. Clinical Nephrology, 71(2), 233 - 235.

Costa, E., Swinkels, D. W., Laarakkers, C. M., Rocha-Pereira, P., et al. (2009). Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients. Acta Haematologica, 122(4), 226 - 229.

Costa, E., Rocha, S., Rocha-Pereira, P., Castro, E., et al. (2008). Altered erythrocyte membrane protein composition in chronic kidney disease stage 5 patients under haemodialysis and recombinant human erythropoietin therapy. Blood Purification, 26(3), 267 - 273.

Costa, E., Rocha, S., Rocha-Pereira, P., Castro, E., et al. (2008). Cross-talk between inflammation, coagulation/fibrinolysis and vascular access in hemodialysis patients. Journal of Vascular Access, 9(4), 248 - 253.

Costa, E., Rocha, S., Rocha-Pereira, P., Reis, F., et al. (2008). DMT1 (NRAMP2/DCT1) Genetic Variability and Resistance to Recombinant Human Erythropoietin Therapy in Chronic Kidney Disease Patients under Haemodialysis. Acta Haematologica, 120(1), 11 - 13.

Costa, E., Rocha, S., Rocha-Pereira, P., Nascimento, H., et al. (2008). Neutrophil activation and resistance to recombinant human erythropoietin therapy in hemodialysis patients. American Journal of Nephrology, 28(6), 935 - 940.

Costa, E., Pereira, B. J. G., Rocha-Pereira, P., Rocha, S., et al. (2008). Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients. American Journal of Nephrology, 28(4), 677 - 683.